What Big CROs Don't Want You To Know About Staffing Scalability For Phase III Studies
The stakes are high in critical indication studies, and it’s crucial that the teams working on them understand the nuances of those specific therapeutic areas. But when large CROs need to scale up for Phase III studies, sponsors rarely get the people they actually need. The dark side of staffing scalability—rolling the dice on random employees, pulling personnel from existing business, poaching from other CROs—inhibit the CRO’s ability to build teams that will benefit the study, rather than simply get the job done.
Take a deeper dive into the limitations of the standard CRO staffing model, and then find out how you can get the driven, passionate, therapeutically aligned team your study deserves.
